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Dynamic changes in biomarkers in acute 
human immunodeficiency virus infections:  
a case report
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Abstract 
Background: The highest incidence of human immunodeficiency virus infection in China is among men who have 
sex with men. This case report aims to describe the dynamic changes in biomarkers in an acute human immunode‑
ficiency virus infection of a Han Chinese man who has sex with men, and to illustrate the possibility of using these 
biomarkers for the early detection of human immunodeficiency virus infection in Chinese hospital settings.
Case presentation: The 25‑year‑old Han Chinese male patient presented himself with an 8‑day history of symptoms 
and signs of upper respiratory viral infections to a sexually transmitted infection clinic of a hospital setting in Shang‑
hai. The viral load of human immunodeficiency virus, p24 antigen–antibody complex, and lymphocyte subsets of 
blood samples were repeatedly measured over the next 39 days. The human immunodeficiency virus from serum was 
genotyped. This patient was diagnosed as a human immunodeficiency virus infection, and the viral genotype was 
CRF 01_AE. The onset of the symptoms and signs was 12 days after his last reported unprotected intercourse with a 
human immunodeficiency virus ‑infected man. The patient had detectable levels of p24 antigen at his first visit, 20 days 
after infection, and the HIV viral load was at the highest point (8 × 106 copies/ml). A low concentration of antibody to 
HIV was observed in the patient’s serum 10 days after his 1st visit (30 days after infection). The confirmation of human 
immunodeficiency virus infection by Western blot assays was made at day 20 after his 1st visit (40 days after infection).
Conclusions: Symptoms of acute human immunodeficiency virus infection are non‑specific. Specific laboratory 
markers appear shortly after HIV infections. The first biomarker detected from serum is the viral RNA and p24 antigen, 
followed by HIV‑specific antibody. The results suggest that there are urgent needs for both human immunodeficiency 
virus antigen and antibody testing in routine medical practice, and that human immunodeficiency virus RNA testing 
should be recommended to detect early infection. Ethics approval was obtained from the Ethics Board of the Shang‑
hai Dermatology Hospital.
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Background
By 2014, it was estimated that 0.78 (0.62–0.94) million 
people were living with human immunodeficiency virus 
(HIV) in China [1]. More than 90% of all reported cases 
were infected through sexual transmission  [1]. While 
HIV prevalence among the general population in China 
remains low at 0.058%, early detection of HIV infection 
in high risk populations, such as men who have sex with 
men (MSM) and female sex workers (FSW), is of great 
importance [2, 3].
The timing of the appearance of viral and host markers 
in HIV infection has been well characterized [4]. It has 
been shown that the natural history of HIV infections 
remain the same no matter whether the virus is sexually 
transmitted or by the transmission route of intravenous 
inoculations [4]. The natural history of HIV infections 
can be divided into six stages. Viral RNA in plasma is the 
first detectable markers, followed by viral antigens, and 
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then host specific antibodies [4]. This indicates that early 
diagnosis of acute HIV infection will rely on the detec-
tion of viral RNA and viral protein antigens.
Currently, there are three distinct testing paradigms of 
HIV testing in China, i.e. voluntary counseling and testing 
(VCT), high-risk group testing, and provider initiated test-
ing and counseling (PITC) [5]. The first two are typically 
set in the public health system, specifically in the Centre 
for Disease Prevention and Control (CDC) and in the facil-
ities for blood donation and family planning. In contrast, 
patients with primarily sexual health complaints, whether 
they are heterosexual or homosexual, commercial sex 
workers or not, the local clinics, especially clinics for sexu-
ally transmitted infections (STIs), are the most frequently 
visited health facilities for the diagnosis and treatment of 
HIV. When patients are seen by clinical facilities, they are 
more likely to get tested for HIV through PITC.
Currently in China, screening of HIV infection is 
mainly performed using antibody-based tests such as the 
enzyme-linked immunosorbent assays (ELISA), followed 
by confirmatory tests using the Western blot assays [6].
Unfortunately, risk-based screening for antibodies to 
HIV is usually not sensitive enough for early diagnosis, 
and may fail to identify HIV-infected individuals dur-
ing the first several weeks following acquisition [7]. The 
improvement in the sensitivity of serologic tests (e.g., the 
HIV p24 antigen assay) [8], the detection of HIV viral 
load, and more recently the implementation of the HIV 
nucleic acid test (NAT) which can detect HIV RNA have 
all further reduced the delay in detecting acute infec-
tion [9–12]. HIV viral RNA is detectable approximately 
7–11 days after HIV infection [4].
Currently in China’s hospitals, particularly in STI-
specialized hospitals, there is more frequent use of anti-
gen–antibody combination-based fourth generation HIV 
tests, which enhances the potential for timely detection 
of HIV infection in early stages. However, very little 
information on the early detection of acute HIV infec-
tion in China has been reported. Here we report a case 
of acute HIV infection in a MSM in Shanghai, China. 
Repeated measurements of the patient’s HIV viral load, 
p24 antigen–antibody complex, and lymphocyte subsets 
were taken. The aims of this case report are to describe 
the dynamic changes in these biomarkers in a patient 
with an acute HIV infection and to illustrate the possibil-
ity of detecting HIV infection in the window before the 
presence of HIV antibodies in clinical settings.
Case presentation
Demographic characteristics and history
Ethics approval was obtained from the Ethics Board of 
the Shanghai Dermatology Hospital. A 25-year old male 
Han Chinese patient presented himself to a STI clinic of 
a hospital in Shanghai. The patient had an 8-day-duration 
of a low fever (~38 °C), sore throat, periodontitis and torso 
rash before hospital admission. The patient was extremely 
worrying himself being infected with HIV. He had been 
engaging in MSM for about 8 years. He had met his latest 
male partner through internet 2 months ago and had sev-
eral unprotected anal intercourses in the past 35 days. The 
last unprotected sex with his male partner occurred 10 days 
ago. The patient had received routine health check-up 
including HIV screening testing. The last health check-up 
was done 2 months ago, and HIV antibody testing was neg-
ative at that time. According to the HIV surveillance data in 
Shanghai Municipal CDC, the partner was confirmed with 
HIV infection 2 years ago; however, the patient had never 
been informed of his partner’s HIV status. The patient 
had unprotected anal intercourse with this MSM partner 
10 days before the onset of the above symptoms and signs. 
The patient had no history of drug use or surgery. The 
patient was treated and currently is being followed up.
Methods and results of laboratory testing
Blood samples of the patient were collected at the 1st 
visit on Day 1, 8  days after the onset of symptoms and 
signs, and at follow-up visits until Day 39 (Fig.  1). Bio-
markers tested included HIV RNA load, HIV-p24 anti-
gen, HIV antibody and blood lymphocyte CD4/CD8 
counts and ratios. Briefly, the HIV RNA load was quan-
tified by RT-PCR [Easy Q NASBA HIV-1 v2.0 (BioMé-
rieux Clinical Diagnostics, Co., Ltd, Shanghai, China) 
and MyCycler™ thermal cycler (Bio-Rad Laboratories 
Co., Ltd, Shanghai, China)]. The HIV-p24 antigen was 
determined using VIDAS HIV DUO Ultra assay (Bio-
Mérieux Clinical Diagnostics, Co., Ltd). Confirmatory 
tests using the Western blot testing for HIV antibody 
was performed [HIV BLOT 2.2 MP diagnostics (MP Bio-
medicals Co., Ltd. Singapore)]. The HIV virus was also 
genotyped using the nested RT-PCR followed by DNA 
sequencing analysis [Clustal X program in MEGA5 soft-
ware version 4.9, Center for Evolutionary Medicine and 
Informatics, The Biodesign Institute, Tempe, Arizona]. 
Drug-resistance associated mutations in protease and 
reverse transcriptase regions of the virus were also ana-
lyzed (Stanford University HIV/AIDS Drug Resistance 
Database; http://hivdb.stanford.edu/). The lymphocyte 
subsets were measured using the flow cytometry (Bec-
ton–Dickinson Medical Devices Co., Ltd., Shanghai).
HIV viral RNA was first detected on Day 1, about 
20  days after the last incidence of unprotected inter-
course and 8 days after the onset of symptoms and signs. 
The viral load on Day 1 was 8.0 × 106 copies/ml. A sharp 
decrease in the viral load was observed between day 1 
and day 16. The viral load after Day 16 remained was sta-
ble with approximately 1.0 × 105 copies/ml (Fig. 1).
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The HIV-p24 antigen was also first detected on day 
1. The signal-to-cut-off (S/CO) values of p24 antigen 
declined quickly from 8.97 on day 1 to 1.35 on day 10. On 
day 12, the p24 antigen was no longer detectable in the 
serum.
HIV antibody in the serum was undetectable until day 
10. The levels of HIV antibody titres rose after day 10, but 
remained low during the first 20  days of examinations. 
Western blot tests revealed only weak reactions in some 
of the bands during the same period and had a strong 
reaction on day 20.
The total counts of CD4+ T cells remained stable 
throughout the observation period. The percentage of 
CD4+ T cells was around 16% at the first two follow-up 
visits, and persisted at 6–8% from day 8 onward. The per-
centage of CD8+ cells underwent a sudden increase from 
39% on day 2 to 69% on day 8, and persisted at this level 
through the follow-up period. The CD4+/CD8+ ratio var-
ied from 0.4 on day 2 to 0.1 on day 8.
The HIV virus had a genotype of CRF 01_AE. There were 
no mutations in the resistant genes for drugs of nucleoside 
reverse transcriptase inhibitors, non-nucleoside reverse 
transcriptase inhibitors and protease inhibitors.
Conclusions
The reported case is an acute HIV-CRF 01_AE infec-
tion in a Han Chinese male patient who had unpro-
tected sex with a HIV infected man. The virus RNA and 
p24 biomarkers were detectable in the serum at early 
time of the infection. Viral RNA appeared high titre on 
the first day of visit. HIV-specific antibody was detect-
able after the appearance of HIV virus and HIV antigen. 
The dynamic changes in these biomarkers were consist-
ent with the natural history and immune-pathogenesis 
of a typical HIV infection [4]. Most HIV screening tests 
in Chinese clinical settings detect antibodies but not 
viral antigen proteins or RNA [12, 13]. In the absence of 
antibodies, p24 antigen and RNA typically indicate acute 
HIV infection. Combined viral antigen and specific anti-
body may still miss HIV infections in acute stages (i.e. 
within 20 days after HIV acquisition) [4, 12]. This study 
suggests that detection of HIV virus RNA and HIV-p24 
antigen in the serum are required for early diagnosis of 
HIV infections and recommends an urgent need for anti-
gen–antibody combination-based HIV tests in clinical 
settings. In settings with appropriate facilities, HIV virus 
RNA testing should be recommended to detect early HIV 
infection.
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Fig. 1 Dynamic changes of biomarkers in a HIV‑infected patient. Day 0: the day of the patient’s first hospital visit. S/CO signal‑to‑cut‑off, HIV‑p24 Ag 
human immunodeficiency virus p24 antigen, HIV‑Ab human immunodeficiency virus antibody, HIV‑VL human immunodeficiency viral load
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